The endoscopy devices market is projected to increase from USD 35.9 billion in 2026 to USD 50.4 billion in 2031, representing a CAGR of 7.0% during the forecast period.

Market Overview

Endoscopy is moving from a largely visualization-led equipment category toward a connected procedural platform combining scopes, processors, displays, operative devices, imaging software and AI. Olympus is commercializing its OLYSENSE intelligent endoscopy ecosystem, including cloud-based computer-aided detection, while its 2026 product launches include a flexible-tip videoscope supporting 4K, 3D and infrared imaging. Fujifilm is extending the ELUXEO 8000 portfolio with next-generation therapeutic gastroscopes, colonoscopes and duodenoscopes, and is also localizing endoscopy-system manufacturing in India. These developments support both replacement demand in mature hospitals and broader adoption in fast-expanding healthcare systems.

Procedure mix is also changing. Diagnostic colonoscopy and upper gastrointestinal endoscopy remain high-volume anchors, but advanced therapeutic procedures are increasing equipment intensity through specialized channels, cutting and closure devices, endoscopic ultrasound, and robotic assistance. Single-use scopes address infection-control and workflow requirements where reprocessing is costly or difficult, particularly in bronchoscopy and urology. At the same time, outpatient migration supports compact systems and faster turnover, while high-acuity tertiary centres continue to invest in premium imaging and complex therapeutic platforms.

Selected Segment Estimates

Market Dynamics

Drivers

Rising endoscopic procedure intensity. Endoscopy increasingly combines diagnosis and treatment in the same care pathway. Colorectal cancer screening, gastrointestinal lesion surveillance, bronchoscopy, urological procedures and minimally invasive surgery create repeat demand for scopes, processors, accessories and operative devices. As health systems prioritize earlier diagnosis and less invasive treatment, procedure volumes and the value of equipment used per procedure both rise.

Technology-led replacement cycles. New systems are adding 4K and 3D imaging, infrared modes, advanced image enhancement, AI-enabled lesion detection, and cloud connectivity. These capabilities shorten the useful commercial life of older visualization platforms and encourage hospitals to standardize around integrated ecosystems. Software-based functionality also creates a recurring revenue layer beyond one-time capital purchases.

Growth of single-use and therapeutic endoscopy. Disposable bronchoscopes, ureteroscopes and selected gastrointestinal scopes reduce reprocessing requirements and contamination risk, while therapeutic endoscopy increases demand for high-value accessories and dedicated scopes. This expands market revenue even where installed reusable-scope penetration is already high.

Restraints

High capital expenditure and reprocessing costs remain important constraints, particularly for smaller hospitals in emerging markets. Complex reusable systems require cleaning infrastructure, maintenance, trained personnel, and downtime management. At the same time, single-use products can increase per-procedure cost and medical waste, limiting adoption where reusable fleets are economically efficient. Regulatory scrutiny, recalls, and cybersecurity requirements for connected systems can also slow product rollouts and replacement decisions.

Segment Analysis

By Device Type: Endoscopes

Endoscopes remain the largest device category, accounting for approximately 35% of 2026 market revenue. Flexible gastrointestinal scopes dominate the installed base, while rigid scopes remain central to laparoscopy and surgical specialties. The fastest value expansion is concentrated in high-function therapeutic scopes and single-use devices. Ambu continues to broaden its single-use endoscopy portfolio, while Fujifilm and Olympus are extending premium therapeutic and imaging capabilities. Robot-assisted and endoluminal technologies remain smaller in revenue terms but are important because they can expand the range of lesions treated endoscopically rather than surgically.

By Technology: AI-Integrated Endoscopy

AI-integrated endoscopy is emerging as the fastest-growing technology layer rather than a standalone replacement for conventional video endoscopy. Olympus has positioned OLYSENSE as a cloud-based ecosystem for computer-aided detection and related applications, while broader industry development is moving toward real-time lesion characterization, automated documentation, and procedure-quality analytics. Adoption is strongest in colonoscopy because clinical endpoints such as adenoma detection are measurable, but the same architecture can extend into upper gastrointestinal, pulmonary, and surgical workflows.

Technology and Demand Indicators

Geographical Outlook:

North America Analysis

North America accounts for approximately 37% of global endoscopy-device revenue in 2026, with the United States providing the majority of regional demand. The region combines high screening and procedure volumes with rapid adoption of premium visualization, single-use scopes, and AI-enabled software. Ambulatory surgical centres are especially important because gastrointestinal and minimally invasive procedures continue to migrate toward outpatient settings, increasing demand for systems that support fast turnover and standardized workflows. The United States also remains a major launch market for new endoscopy technologies because FDA clearance can accelerate commercial adoption and support global reference-site development.

The regional growth mix is shifting from basic installed-base expansion toward technology replacement and recurring revenue. Recent 2026 clearances and launches span disposable gastroscopes, advanced GI videoscopes, AI applications and next-generation surgical imaging. This creates a layered revenue opportunity involving processors, scopes, displays, operative devices, software subscriptions, disposables and service contracts. Canada contributes a smaller but technologically advanced market, while Mexico adds procedure-volume growth and private-hospital investment, particularly in major urban centres.

Competitive Landscape

The competitive landscape combines broad endoscopy-platform companies with focused device specialists. Olympus maintains a particularly strong position across gastrointestinal endoscopy, surgical imaging and endotherapy, while Fujifilm competes through ELUXEO imaging, therapeutic scopes and expanding regional manufacturing and service capacity. Karl Storz and Stryker are important in surgical endoscopy and visualization, and PENTAX Medical remains established in gastrointestinal and pulmonary endoscopy. Boston Scientific and Medtronic participate heavily through therapeutic devices and procedure-enabling technologies, while Ambu is a major growth competitor in single-use endoscopy. Intuitive Surgical and specialized robotic developers are extending competition into endoluminal and robot-assisted procedures.

Recent Developments

• August 2026: Olympus launched the ENDOEYE FLEX 3D flexible-tip videoscope supporting 4K, 3D and infrared imaging.

• August 2026: Fujifilm India expanded the ELUXEO 8000 portfolio with next-generation therapeutic gastroscopes and related gastrointestinal scopes.

• May 2026: Olympus signed an exclusive global distribution agreement with EndoRobotics for robot-assisted endotherapy technologies.

• May 2026: Fujifilm launched the EB-710US next-generation balloon-less endobronchial ultrasound bronchoscope in the United States.

• February 2026: Olympus reported results from the EAGLE trial evaluating the cloud-based CADDIE AI solution for colorectal-polyp detection.

• February 2026: Fujifilm inaugurated localized endoscopy-system manufacturing in Jodhpur, India.

Endoscopy Devices Market Scope: